arachidonyl-2-chloroethylamide has been researched along with Dyskinesia--Drug-Induced* in 1 studies
1 other study(ies) available for arachidonyl-2-chloroethylamide and Dyskinesia--Drug-Induced
| Article | Year |
|---|---|
Arachidonyl-2'-chloroethylamide (ACEA), a synthetic agonist of cannabinoid receptor, increases CB
l-Dopa is the most effective drug used for Parkinson's disease (PD), but after long-term treatment, the vast majority of PD patients develop abnormal involuntary movements (AIMs) termed l-Dopa-induced dyskinesia (LID). Cannabinoid receptors in the basal ganglia can modulate motor functions, but their role in the treatment of LID is controversial. Therefore, the aim of this study is to evaluate the motor behavior and mRNA expression of the cannabinoid receptor-1 (CB Topics: Animals; Arachidonic Acids; Cannabinoid Receptor Agonists; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Gene Expression; Levodopa; Male; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; RNA, Messenger | 2020 |